RIGL vs HALO

For growth investors, Rigel Pharmaceuticals, Inc.

(RIGL) is the stronger pick with 64. 1% revenue growth year-over-year, versus 37. 6% for Halozyme Therapeutics, Inc. (HALO). Rigel Pharmaceuticals, Inc. (RIGL) offers the better valuation at 1. 4x trailing P/E (6. 1x forward), making it the more compelling value choice. Analysts rate Rigel Pharmaceuticals, Inc. (RIGL) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Rigel Pharmaceuticals, Inc.

(RIGL) is the cheapest at 1. 4x versus Halozyme Therapeutics, Inc. at 25. 9x. On forward P/E, Rigel Pharmaceuticals, Inc. is actually cheaper at 6. 1x.

Over the past 5 years, Halozyme Therapeutics, Inc.

(HALO) delivered a total return of +39. 1%, compared to -18. 2% for Rigel Pharmaceuticals, Inc. (RIGL). Over 10 years, the gap is even starker: HALO returned +598. 4% versus RIGL's +15. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.

(HALO) is the lower-risk stock at 0. 56β versus Rigel Pharmaceuticals, Inc. 's 1. 03β — meaning RIGL is approximately 85% more volatile than HALO relative to the S&P 500.

By revenue growth (latest reported year), Rigel Pharmaceuticals, Inc.

(RIGL) is pulling ahead at 64. 1% versus 37. 6% for Halozyme Therapeutics, Inc. (HALO). On earnings-per-share growth, the picture is similar: Rigel Pharmaceuticals, Inc. grew EPS 1868% year-over-year, compared to -25. 4% for Halozyme Therapeutics, Inc.. Over a 3-year CAGR, RIGL leads at 34. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Rigel Pharmaceuticals, Inc.

(RIGL) is the more profitable company, earning 124. 7% net margin versus 22. 7% for Halozyme Therapeutics, Inc. — meaning it keeps 124. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus 42. 6% for RIGL. At the gross margin level — before operating expenses — RIGL leads at 93. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Rigel Pharmaceuticals, Inc.

(RIGL) trades at 6. 1x forward P/E versus 8. 2x for Halozyme Therapeutics, Inc. — 2. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RIGL: 50. 0% to $40. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 56), +598. 4% 10Y return). Both have compounded well over 10 years (HALO: +598. 4%, RIGL: +15. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.